Results 51 to 60 of about 6,241 (179)

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

An Nfil3–Zeb2–Id2 pathway imposes Irf8 enhancer switching during cDC1 development [PDF]

Nature Immunology, 2019
Classical type 1 dendritic cells (cDC1s) are required for antiviral and antitumor immunity, which necessitates an understanding of their development. Development of the cDC1 progenitor requires an E-protein-dependent enhancer located 41 kilobases downstream of the transcription start site of the transcription factor Irf8 (+41-kb Irf8 enhancer), but its
Prachi Bagadia, Xiao Huang, Tian-Tian Liu, Vivek Durai, Gary E. Grajales-Reyes, Maximilian Nitschké, Zora Modrusan, Jeffrey M. Granja, Ansuman T. Satpathy, Carlos G. Briseño, Marco Gargaro, Arifumi Iwata, Sunkyung Kim, Howard Y. Chang, Andrey S. Shaw, Theresa L. Murphy, Kenneth M. Murphy   +16 more
openaire   +2 more sources

Batf3-dependent orchestration of the robust Th1 responses and fungal control during cryptococcal infection, the role of cDC1

mBio
While type I conventional dendritic cells (cDC1s) are vital for generating adaptive immunity against intracellular pathogens and tumors, their role in defense against fungal pathogen Cryptococcus neoformans remains unclear.
Jintao Xu, Rylan Hissong, Rachel Bareis, Arianna Creech, Kristie D. Goughenour, Christine M. Freeman, Michal A. Olszewski   +6 more
doaj   +1 more source

Type 1 Conventional CD103+ Dendritic Cells Control Effector CD8+ T Cell Migration, Survival, and Memory Responses During Influenza Infection

Frontiers in Immunology, 2018
Type 1 conventional CD103+ dendritic cells (cDC1) contribute significantly to the cytotoxic T lymphocyte (CTL) response during influenza virus infection; however, the mechanisms by which cDC1s promote CTL recruitment and viral clearance are unclear.
See Liang Ng, Yi Juan Teo, Yolanda Aphrilia Setiagani, Klaus Karjalainen, Christiane Ruedl   +4 more
doaj   +1 more source

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source

cDC1-derived IL-27 regulates small intestinal CD4+ T cell homeostasis in mice

Journal of Experimental Medicine, 2022
The small intestinal lamina propria contains large numbers of IFNγ-producing T helper (Th1) cells that play important roles in intestinal homeostasis and host defense, but the mechanisms underlying their development remain poorly understood. Here, we demonstrate that Th1 cells accumulate in the SI-LP after weaning and are maintained there long term ...
Fatemeh Ahmadi, Fredrik Junghus, Christian Ashworth, Amanda Lappalainen, Urs Mörbe, Knut Kotarsky, William W. Agace   +6 more
openaire   +3 more sources

Lung cDC1 and cDC2 dendritic cells priming naive CD8+ T cells in situ prior to migration to draining lymph nodes

Cell Reports, 2023
Summary: The current paradigm indicates that naive T cells are primed in secondary lymphoid organs. Here, we present evidence that intranasal administration of peptide antigens appended to nanofibers primes naive CD8+ T cells in the lung independently ...
Youhui Si, Yihan Wang, Qiaomu Tian, Qiang Wang, Jared M. Pollard, Pramod K. Srivastava, Aaron P. Esser-Kahn, Joel H. Collier, Anne I. Sperling, Anita S. Chong   +9 more
doaj   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Enhancing tumor immunity via in vivo cDC1 reprogramming

Trends in Immunology
A recent study by Ascic et al. demonstrates that in situ reprogramming of tumor cells into conventional dendritic cell (cDC)-like cells using viral-PIB transcription factors creates an immunogenic tumor microenvironment with T cell recruitment and activation.
Yoojung, Kwon, Kyunghee, Choi
openaire   +2 more sources